Evidence map›Paper›PMID 25771895›Full record

Trial reportHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2015

Hypovitaminosis D and organ damage in patients with arterial hypertension: a multicenter double blind randomised controlled trial of cholecalciferol supplementation (HYPODD) : study design, clinical procedures and treatment protocol.

Domenico Rendina, Renato Ippolito, Lanfranco D'Elia, Gilberta Giacchetti, Chiara Lonati, Fernando Gianfrancesco, Francesco Fallo, Andrea Rebellato, Carmelinda Ruggiero, Speranza Rubattu and 13 more

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 1 country.

Domenico RendinaDepartment of Clinical Medicine and Surgery, Excellence Center of Hypertension, ''Federico II University'' Medical School, via Sergio Pansini 5, 80131, Naples, Italy, domenico.rendina@unina.it.
Renato Ippolito
Lanfranco D'Elia
Gilberta Giacchetti
Chiara Lonati
Fernando Gianfrancesco
Francesco Fallo
Andrea Rebellato
Carmelinda Ruggiero
Speranza Rubattu
Massimo Volpe
Luigi Gennari
Daniela Merlotti
Gian Carlo Isaia
Patrizia D'Amelio
Elena Spertino
Bruno Fabris
Leonardo A Sechi
Cristiana Catena
Andrea M Maresca
Vera Gessi
Andrea Dalbeni
Pasquale Strazzullo
Federico II University Hospital · ITUniversity of Turin · ITIstituto Neurologico Mediterraneo · ITUniversity of Insubria · ITUniversity of Padua · ITUniversity of Siena · ITUniversity of Udine · ITInstitute of Genetics and Biophysics · ITOspedali Riuniti Umberto I · ITUniversity of Milan · ITUniversity of Perugia · ITUniversity of Trieste · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAt this time, good quality randomized clinical trials assessing the effects of vitamin D supplementation on cardiometabolic outcomes are lacking in the international literature.

aimTo fill this gap, the Working Group on Vitamin D and Cardiorenal Disorders established jointly by the Italian Society of Hypertension (SIIA) and the Forum in Bone and Mineral Research conceived the HYPODD study (HYPOvitaminosis D and organ Damage).

methodsHYPODD is a no-profit multicenter 12-month parallel-group double-blind placebo controlled randomized trial aiming to assess the effects of cholecalciferol supplementation on blood pressure control, antihypertensive drugs consumption and progression of target organ damage in patients with essential hypertension and 25-hydroxyvitamin D serum level lower than 20 ng/ml (vitamin D deficiency). HYPODD is coordinated by the European Society Excellence Center of Hypertension of Federico II University, Naples, and involves 12 academic institutions in Italy (Ancona, Milan, Padua, Perugia, Rome, Siena, Trieste, Turin, Udine, Varese, and Verona). RESULTS AND

conclusionThe HYPODD study has been registered at the Agenzia Italiana del Farmaco-Osservatorio sulla Sperimentazione Clinica del Farmaco (AIFA-OsSC) and EUDRACT sites (n° 2012-003514-14) and has been approved by the Ethical Committees of all the Centers involved in the study. The patients' recruitment is currently underway.

Indexed as

Dietary SupplementsAntihypertensive AgentsArterial PressureBiomarkersCholecalciferolClinical ProtocolsDisease ProgressionDouble-Blind MethodHumansHypertensionItalyPatient SelectionSample SizeTime FactorsTreatment OutcomeVitamin D25-hydroxyvitamin DAntihypertensive AgentsBiomarkersCholecalciferolVitamin D

Identifiers

PMID25771895
OpenAlexW1607192067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.